Immunovant (IMVT) reported a fiscal Q3 loss Thursday of $0.76 per diluted share, wider than a loss of $0.36 a year earlier.
Four analysts polled by FactSet expected a loss of $0.73.
As of Dec. 31, 2024, the company said it had cash and cash equivalents of $374.7 million.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。